On July 20, 2026, Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to sell up to $4,000,000 of common stock. Aegis Capital Corp. will act as the exclusive sales agent and receive a commission of 3.0% of the gross proceeds. The shares will be issued under a shelf registration statement on Form S-3. Sunshine Biopharma Inc. is a biopharmaceutical company.
